Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Papillary Thyroid Cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback